Nili MED's first product is a new type of insulin pump that is expected to be safer, more efficient, and less expensive than existing products. David Vita (88-90 MIL), VP Marketing stated that "the technology allows for a very low flow rate delivery and continuous flow control - ideal conditions for the administration of insulin." "Other applications for which this technology is particularly suitable include drug delivery in chemotherapy."
The ADI insulin pump uses a pressurized reservoir and a series of valves to control flow and detect malfunctions along the delivery line.
Vita explains that the main limiting factors of current insulin pump models is that all current technology insulin pumps on the market today operate on the principle of the syringe pump, although many improvements have been made this technology has reached its limits. It's difficult for the syringe pump technology to administer the children dosage of 0.5 units per hour and requiring 2.5 micron displacement of the plunger every 3 minutes.
Another complication is hypoglycemia that can occur when substantial amounts of occluded insulin are suddenly released and delivered to the patient or when the patient, unaware of the true amount of insulin deposited in the catheter, decides to use an insulin bolus to balance a perceived high glucose rate. Nili MED technology mimics at best the human pancreas because it continuously checks the persistence of the basal rate.
Current insulin pumps can cost over $5,000 and their size makes them inconvenient to the patient and their alarm systems do not fully cover all possible malfunctions, says Vita. Vita expects the ease of use and low manufacturing cost of the ADI pump to enable the gradual market penetration of untapped potential pump users, as well as open competition with current pumps.
Nili MED was established in 2002 with the framework of the Technion Entrepreneurial Incubator Company (TEIC) in Northern Israel. The company expects to be in clinical trials in 2005.